Where I see patients (4)
Selected research
-
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
The Lancet. Oncology
-
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
Journal of the National Cancer Institute
-
International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology.
European journal of nuclear medicine and molecular imaging
Clinical trials
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
The proportion of patients who achieve a greater than 50% decline from baseline prostate specific antigen (PSA) (PSA50) drawn prior to C1D1, at any point in the treatment course, will be descriptively reported along with 95% binom...
Recruiting
18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas
Sensitivity of 18F-fluorocholine PET for the detection of abnormal parathyroid adenomas confirmed by pathology as compared to sestamibi imaging. Location of parathyroid adenoma at imaging as read by three blinded readers, will be ...
Recruiting
Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors
Radiologists will classify lesions as having recurrent disease or not having recurrent disease. True Positives (TP) are defined as an FET PET read positive for tumor and pathology/follow-up demonstrates tumor recurrence in at leas...
Recruiting